MRNA (messenger ribonucleic acid) tumor vaccine for improving DCs (dendritic cells) disability in tumor immune microenvironment as well as preparation method and application of mRNA tumor vaccine

The invention relates to an mRNA (messenger Ribonucleic Acid) tumor vaccine for improving DCs (Dendritic Cancer) disability in a tumor immune microenvironment as well as a preparation method and application thereof. The mRNA tumor vaccine is constructed from a cation compound loaded with alpha-galac...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: YANG JIANHONG, QIAO FANGXIA, MA SHIJIE, GUO JUESHUO, LI ZHIFANG, MAI YAPING
Format: Patent
Sprache:chi ; eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The invention relates to an mRNA (messenger Ribonucleic Acid) tumor vaccine for improving DCs (Dendritic Cancer) disability in a tumor immune microenvironment as well as a preparation method and application thereof. The mRNA tumor vaccine is constructed from a cation compound loaded with alpha-galactosylceramide (alpha-Galcer), protamine and mRNA, the alpha-Galcer is adsorbed to a phospholipid layer of the compound, and a protamine-HER2 mRNA condensation compound is wrapped in an inner core of the compound. The mRNA tumor vaccine constructed by the invention can be used for immunotherapy through subcutaneous injection or intramuscular injection or nasal mucosa, and can stimulate DCs cells to be mature and secrete cell factors. After mice are immunized, the novel mRNA tumor vaccine can effectively promote T cell proliferation and activation, exert congenital and adaptive immune response, improve the inhibition effect of a tumor immune microenvironment and effectively enhance anti-tumor immune response. 本发明涉及一种